{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Fit-takes-2-to-tyk2-part2-pdCnw3R4","width":444,"version":"1.0","type":"rich","title":"It Takes 2 to TYK2 with Dr.Marissa Joseph and Dr.Geeta Yadav PART 2","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/96ca18e5-265b-44af-bb14-43fc1bec3cc8/part2new.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/03a3a792-00f6-47d5-84fd-933cc2e04406\" height=\"200\" width=\"100%\" title=\"It Takes 2 to TYK2 with Dr.Marissa Joseph and Dr.Geeta Yadav PART 2\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"💡💡💡 𝐃𝐫.𝐘𝐚𝐝𝐚𝐯 𝐚𝐧𝐝 𝐃𝐫.𝐉𝐨𝐬𝐞𝐩𝐡 𝐥𝐨𝐨𝐤 𝐭𝐨 𝐬𝐞𝐭𝐭𝐥𝐞 𝐭𝐡𝐞 𝐝𝐞𝐛𝐚𝐭𝐞 𝐢𝐧 𝐏𝐀𝐑𝐓 𝐈𝐈 𝐨𝐟 𝑰𝑻 𝑻𝑨𝑲𝑬𝑺 2 𝑻𝑶 𝑻𝒀𝑲 2.\n\n🟢𝐇𝐚𝐯𝐞 𝐲𝐨𝐮 𝐛𝐞𝐞𝐧 𝐰𝐨𝐧𝐝𝐞𝐫𝐢𝐧𝐠 𝐰𝐡𝐚𝐭'𝐬 𝐭𝐡𝐞 𝐫𝐞𝐚𝐥 𝐝𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐜𝐞 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 #𝐉𝐀𝐊 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 #𝐓𝐘𝐊-𝟐 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐢𝐨𝐧? 𝐀𝐫𝐞𝐧'𝐭 𝐭𝐡𝐞𝐲 𝐩𝐚𝐫𝐭 𝐨𝐟 𝐭𝐡𝐞 𝐬𝐚𝐦𝐞 𝐩𝐚𝐭𝐡𝐰𝐚𝐲? \n𝗪𝗲𝗹𝗹 𝘄𝗲 𝘁𝗮𝗸𝗲 𝗮 𝗱𝗲𝗲𝗽 𝗱𝗶𝘃𝗲 𝗶𝗻𝘁𝗼 𝘁𝗵𝗲 𝘀𝗮𝗳𝗲𝘁𝘆 𝗰𝗼𝗻𝘃𝗲𝗿𝘀𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 seek clarify for you when it comes to all you need to know about key 𝗧𝗬𝗞 𝘃𝘀 𝗝𝗔𝗞 𝘀𝗶𝗱𝗲 𝗲𝗳𝗳𝗲𝗰𝘁 𝗮𝗻𝗱 𝗺𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗰𝗼𝗻𝘀𝗶𝗱𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝘀.\n\nOur experts 𝗮𝗹𝘀𝗼 𝗯𝗿𝗲𝗮𝗸𝗱𝗼𝘄𝗻  𝗣𝗢𝗘𝗧𝗬𝗞-𝟭 𝗮𝗻𝗱 𝗣𝗢𝗘𝗧𝗬𝗞-𝟮 𝗮𝗻𝗱 𝘀𝗵𝗮𝗿𝗲 𝘁𝗵𝗲𝗶𝗿 𝗰𝗮𝗻𝗱𝗶𝗱 𝘁𝗵𝗼𝘂𝗴𝗵𝘁𝘀 𝗼𝗻 𝘄𝗵𝗲𝗿𝗲 𝘁𝗵𝗲𝘆 𝘀𝗲𝗲 𝘁𝗵𝗲 𝗽𝗹𝗮𝗰𝗲 𝗼𝗳 𝗮 𝗧𝗬𝗞-𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿, 𝗶𝗻 𝘁𝗵𝗲𝗶𝗿 𝗽𝗿𝗮𝗰𝘁𝗶𝗰𝗲𝘀, 𝗳𝗼𝗿 𝘁𝗵𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗳 𝗺𝗼𝗱𝗲𝗿𝗮𝘁𝗲 𝘁𝗼 𝘀𝗲𝘃𝗲𝗿𝗲 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀.\n\n🟢𝘼𝙧𝙚 𝙩𝙝𝙚𝙧𝙚 𝙖𝙣𝙮 𝙥𝙧𝙖𝙘𝙩𝙞𝙘𝙖𝙡 𝙘𝙤𝙣𝙨𝙞𝙙𝙚𝙧𝙖𝙩𝙞𝙤𝙣𝙨 𝙛𝙤𝙧 𝙥𝙖𝙩𝙞𝙚𝙣𝙩𝙨 𝙬𝙝𝙤 𝙖𝙧𝙚  𝙗𝙞𝙤𝙡𝙤𝙜𝙞𝙘 𝙣𝙖ï𝙫𝙚  𝙫𝙚𝙧𝙨𝙪𝙨 𝙗𝙞𝙤 𝙚𝙭𝙥𝙚𝙧𝙞𝙚𝙣𝙘𝙚𝙙?\n\n🟢What 𝐝𝐨𝐞𝐬 #TYK-2 #inhibition mean for 𝐭𝐡𝐞 #𝐩𝐬𝐨𝐫𝐢𝐚𝐬𝐢𝐬 𝐩𝐚𝐭𝐢𝐞𝐧𝐭 treatment landscape?\n\n🟢And when do I recommend an i𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐯𝐞𝐫𝐬𝐮𝐬 𝐨𝐫𝐚𝐥 therapy 𝐟𝐨𝐫 𝐦𝐲 𝐩𝐚𝐭𝐢𝐞𝐧𝐭?\n\n🎫 𝗧𝗵𝗶𝘀 𝗺𝗮𝗿𝗸𝘀 𝗮 𝗳𝗶𝗿𝘀𝘁 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗦𝗸𝗶𝗻 𝗮𝗻𝗱 𝗝𝗼𝗶𝗻𝘁𝘀 𝗣𝗼𝗱𝗰𝗮𝘀𝘁- 𝘄𝗲 𝗵𝗮𝘃𝗲 𝘁𝘄𝗼 𝗴𝘂𝗲𝘀𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝘀 𝗼𝗻 𝘁𝗵𝗲 𝘀𝗵𝗼𝘄 𝗮𝘁 𝘁𝗵𝗲 𝘀𝗮𝗺𝗲 𝘁𝗶𝗺𝗲!\n\n𝗪𝗲 𝗮𝗿𝗲 𝗴𝗼𝗶𝗻𝗴 𝘁𝗼 𝗹𝗼𝗼𝗸 𝗮𝘁 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗶𝘁’𝘀 𝗿𝗼𝗹𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗽𝘀𝗼𝗿𝗶𝗮𝘀𝗶𝘀 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 𝘄𝗶𝘁𝗵 𝗮 𝗳𝗼𝗰𝘂𝘀 𝗼𝗻 𝗮 𝗻𝗲𝘄 𝗼𝗿𝗮𝗹 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗧𝗬𝗞𝟮 𝗶𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿 𝗮𝗴𝗲𝗻𝘁 𝗰𝗮𝗹𝗹𝗲𝗱 𝗱𝗲𝘂𝗰𝗿𝗮𝘃𝗮𝗰𝗶𝘁𝗶𝗻𝗶𝗯 𝗮𝗻𝗱 𝘄𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲𝗹𝘆 𝗰𝗼𝗻𝗳𝗲𝗿𝘀 𝗳𝗿𝗼𝗺 𝗮 𝘀𝗮𝗳𝗲𝘁𝘆 𝗽𝗿𝗼𝗳𝗶𝗹𝗲.\n\n𝗗𝗼𝗲𝘀 𝗶𝘁 𝗧𝗬𝗞 𝗮𝗹𝗹 𝘁𝗵𝗲 𝗯𝗼𝘅𝗲𝘀? 𝗟𝗲𝘁’𝘀 𝗳𝗶𝗻𝗱 𝗼𝘂𝘁!\n\n🎙️🎙️🎙️ 𝐏𝐚𝐫𝐭 II with Dr.Geeta Yadav and Dr.Marissa Joseph!\n\nEpisode Learning Objectives\n\n​​Apply current evidence to key efficacy and safety considerations for the oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib \n Describe the  summary details and potential clinical implications of the  pivotal trials POETYK-1 and POETYK-2 \nDiscuss the role of TYK-2 inhibition in moderate to severe psoriasis and the patient journey\n\nABOUT Dr. Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)\n\n▶️Episode supported by an IME Grant from Bristol Myers Squibb"}